Clicky

CymaBay Therapeutics Inc.(CBAY)

Description: Cymabay Therapeutics, Inc. focuses on developing therapies to treat metabolic diseases. Its lead product candidate is Arhalofenate, which completed five Phase II clinical trials for the treatment of gout. The company's product candidate also includes MBX-8025, a selective agonist that is in a Phase II clinical trial in patients with mixed dyslipidemia; and MBX-2982, an oral, G-protein coupled receptor agonist to treat type II diabetes. Cymabay Therapeutics, Inc. has a development and license agreements with Janssen Pharmaceuticals, Inc. to develop and discover undisclosed metabolic disease target agonists for the treatment of T2DM and other disorders; and a license and development agreement with DiaTex, Inc. to develop and commercialize therapeutic products. The company was formerly known as Metabolex, Inc. Cymabay Therapeutics, Inc. was incorporated in 1988 and is based in Newark, California.


Keywords: Medicine Diabetes Health Care Disorders Therapeutic Products Metabolic Disease Lipid Gout Dyslipidemia Regulus Therapeutics I Diabetes Ii Diabetes Mixed Dyslipidemia

Home Page: www.cymabay.com

CBAY Technical Analysis

7575 Gateway Boulevard
Newark, CA 94560
United States
Phone: 510 293 8800


Officers

Name Title
Mr. Sujal A. Shah Pres, CEO & Director
Dr. Dennis D. Kim M.B.A., M.D., MBA Chief Medical Officer
Mr. Lewis J. Stuart B.A., BA, M.B.A., MBA Chief Commercial Officer
Mr. Daniel Menold VP of Fin.
Dr. Charles A. McWherter Ph.D. Sr. VP, Pres of R&D and Chief Scientific Officer
Mr. Paul T. Quinlan Gen. Counsel, Chief Compliance Officer & Corp. Sec.
Mr. Ken Boehm Sr. VP of HR
Mr. Patrick J. O'Mara Sr. VP of Bus. Devel.
Dr. Robert L. Martin Sr. VP of Manufacturing & Nonclinical Devel.
Ms. Klara A. Dickinson-Eason Chief Regulatory & Quality Assurance Officer

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 5.7554
Price-to-Sales TTM: 0
IPO Date: 2014-02-03
Fiscal Year End: December
Full Time Employees: 59
Back to stocks